The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. DENVER — A phase 3 trial of ulixacaltamide for essential ...

Success by nearly all measures with Praxis Precision Medicines Inc.’s essential tremor phase III candidate, ulixacaltamide, drove the company’s stock up by more than 200% and provided supportive data ...

100% (29/29) of patients experienced platelet count reduction to within normal ranges (150 – 400 x 109/L). 90% (26/29) of patients achieved a platelet count of less than 400 x 109/L without ...